Chrétien Y - Search Results

1

The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.

Corpechot C, Carrat F, Bahr A, Chrétien Y, Poupon RE, Poupon R. Corpechot C, et al. Among authors: chretien y. Gastroenterology. 2005 Feb;128(2):297-303. doi: 10.1053/j.gastro.2004.11.009. Gastroenterology. 2005. PMID: 15685541

2

Biochemical markers of liver fibrosis and lymphocytic piecemeal necrosis in UDCA-treated patients with primary biliary cirrhosis.

Corpechot C, Poujol-Robert A, Wendum D, Galotte M, Chrétien Y, Poupon RE, Poupon R. Corpechot C, et al. Among authors: chretien y. Liver Int. 2004 Jun;24(3):187-93. doi: 10.1111/j.1478-3231.2004.0918.x. Liver Int. 2004. PMID: 15189267

3

Development of autoimmune hepatitis in patients with typical primary biliary cirrhosis.

Poupon R, Chazouilleres O, Corpechot C, Chrétien Y. Poupon R, et al. Among authors: chretien y. Hepatology. 2006 Jul;44(1):85-90. doi: 10.1002/hep.21229. Hepatology. 2006. PMID: 16799997

4

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.

Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillères O, Poupon R. Corpechot C, et al. Among authors: chretien y. Hepatology. 2008 Sep;48(3):871-7. doi: 10.1002/hep.22428. Hepatology. 2008. PMID: 18752324

5

Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis.

Corpechot C, Chrétien Y, Chazouillères O, Poupon R. Corpechot C, et al. Among authors: chretien y. J Hepatol. 2010 Jul;53(1):162-9. doi: 10.1016/j.jhep.2010.02.019. Epub 2010 Mar 31. J Hepatol. 2010. PMID: 20471130

6

Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis.

Corpechot C, Gaouar F, Chrétien Y, Johanet C, Chazouillères O, Poupon R. Corpechot C, et al. Among authors: chretien y. J Hepatol. 2012 Jan;56(1):218-24. doi: 10.1016/j.jhep.2011.03.031. Epub 2011 May 19. J Hepatol. 2012. PMID: 21703179

7

Randomized trial of interferon-alpha plus ursodeoxycholic acid versus interferon plus placebo in patients with chronic hepatitis C resistant to interferon.

Poupon RE, Bonnand AM, Queneau PE, Trépo C, Zarski JPí, Vetter D, Raabe JJ, Thieffin G, Larrey D, Grangé JD, Capron JP, Serfaty L, Chrétien Y, St Marc Girardin MF, Mathiex-Fortunet H, Zafrani ES, Guéchot J, Beuers U, Paumgartner G, Poupon R. Poupon RE, et al. Among authors: chretien y. Scand J Gastroenterol. 2000 Jun;35(6):642-9. doi: 10.1080/003655200750023624. Scand J Gastroenterol. 2000. PMID: 10912666 Clinical Trial.

8

Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone.

Rabahi N, Chrétien Y, Gaouar F, Wendum D, Serfaty L, Chazouillères O, Corpechot C, Poupon R. Rabahi N, et al. Among authors: chretien y. Gastroenterol Clin Biol. 2010 Apr-May;34(4-5):283-7. doi: 10.1016/j.gcb.2010.02.004. Epub 2010 Apr 22. Gastroenterol Clin Biol. 2010. PMID: 20417047 Free article.

9

Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group.

Poupon RE, Bonnand AM, Chrétien Y, Poupon R. Poupon RE, et al. Among authors: chretien y. Hepatology. 1999 Jun;29(6):1668-71. doi: 10.1002/hep.510290603. Hepatology. 1999. PMID: 10347106 Clinical Trial.

10

Quality of life in patients with primary biliary cirrhosis.

Poupon RE, Chrétien Y, Chazouillères O, Poupon R, Chwalow J. Poupon RE, et al. Among authors: chretien y. Hepatology. 2004 Aug;40(2):489-94. doi: 10.1002/hep.20276. Hepatology. 2004. PMID: 15368455

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

169 results

Search Page

Filters